Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease-Reference-Cited by-同舟云学术

Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease

Published:2022-05-11 Issue:9 Volume:96 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Deschambault Yvon¹,Lynch Jessie²,Warner Bryce¹,Tierney Kevin¹,Huynh Denise³,Vendramelli Robert¹,Tailor Nikesh³,Frost Kathy¹,Sajesh Babu¹,LeBlanc Kyle²,Layne Christine²,Lin Lisa²,Tamming Levi⁴⁵,Beniac Daniel²,Booth Stephanie¹⁶,Carpenter Michael²⁶,Safronetz David¹⁶,Li Xuguang⁴⁵,Kobasa Darwyn¹⁶,Cao Jingxin²⁶^ORCID

Affiliation:

1. Zoonotic Disease and Special Pathogens Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada

2. Viral Diseases Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada

3. National Centre for Foreign Animal Diseases, Canadian Food Inspection Agency, Winnipeg, Manitoba, Canada

4. Centre for Biologics Evaluation, Biologic and Radiopharmaceutical Drugs Directorate, HPFB, Health Canada and WHO Collaborating Centre for Standardization and Evaluation of Biologicals, Ottawa, Ontario, Canada

5. Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada

6. Department of Medical Microbiology, College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

Abstract

Continuous emergence of SARS-CoV-2 variants which cause breakthrough infection from the immunity induced by current spike protein-based COVID-19 vaccines highlights the need for new generations of vaccines that will induce long-lasting immunity against a wide range of the variants. To this end, we investigated the protective efficacy of the recombinant COVID-19 vaccine candidates based on a novel VACV ACAM2000 platform, in which an immunoregulatory gene, E3L, was deleted and both the SARS-CoV-2 spike (S) and nucleocapsid (N) antigens were expressed.

Funder

Gouvernement du Canada | Health Canada

Public Health Agency of Canada

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/jvi.00389-22

Reference73 articles.

1. WHO. 2022. COVID-19 vaccine tracker and landscape. World Health Organization Geneva Switzerland. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.

2. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

3. COVID-19 dynamics after a national immunization program in Israel

4. SARS-CoV-2 Variants and Vaccines

5. Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Coronavirus spike protein-based vaccines. Vaccine delivery systems;Medicine in Drug Discovery;2024-09

2. The Key to Increase Immunogenicity of Next-Generation COVID-19 Vaccines Lies in the Inclusion of the SARS-CoV-2 Nucleocapsid Protein;Journal of Immunology Research;2024-05-29

3. Molecular characterization of SARS-CoV-2 nucleocapsid protein;Frontiers in Cellular and Infection Microbiology;2024-05-23

4. A comprehensive review on immunogen and immune-response proteins of SARS-CoV-2 and their applications in prevention, diagnosis, and treatment of COVID-19;International Journal of Biological Macromolecules;2024-02

5. Rendezvous with Vaccinia Virus in the Post-smallpox Era: R&D Advances;Viruses;2023-08-15